Last reviewed · How we verify

NCT06158802: MC-HPV

Evaluation of Human Papillomavirus Vaccine Coverage in Girls and Young Women With Chronic Disease

Completed Last updated 20 November 2025
What this trial tests

trial testing Questionnaire in Human Papillomavirus Vaccine in 223 participants. Completed in 26 June 2025.

Timeline
23 January 2024
Primary endpoint
26 June 2025
26 June 2025

Quick facts

Lead sponsorAssistance Publique - Hôpitaux de Paris
StatusCompleted
Study typeOBSERVATIONAL
Enrollment223
Start date23 January 2024
Primary completion26 June 2025
Estimated completion26 June 2025
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Adults 11 to 20, female only, with Human Papillomavirus Vaccine or Chronic Condition. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of the study is to determine the vaccination coverage rate for human papillomavirus in adolescents aged 11 to 20 with chronic disease and treated at the Necker-Enfants Malades Hospital, compared to a population witnessed adolescent girls aged 11 to 20 years without chronic disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Questionnaire

Trials testing the same drug.

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06158802.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing